Chugai Pharmaceutical Receivables 2020-2024 | CHGCY

Chugai Pharmaceutical receivables for the quarter ending September 30, 2024 were $1.614B, a 10.05% decline year-over-year.

  • Chugai Pharmaceutical receivables for 2023 were $2.274B, a 42.56% decline from 2022.
  • Chugai Pharmaceutical receivables for 2022 were $3.96B, a 22.23% increase from 2021.
  • Chugai Pharmaceutical receivables for 2021 were $3.24B, a 36.03% increase from 2020.

Chugai Pharmaceutical Receivables 2020-2024 | CHGCY

  • Chugai Pharmaceutical receivables for 2023 were $2.274B, a 42.56% decline from 2022.
  • Chugai Pharmaceutical receivables for 2022 were $3.96B, a 22.23% increase from 2021.
  • Chugai Pharmaceutical receivables for 2021 were $3.24B, a 36.03% increase from 2020.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$73.8B
Takeda Pharmaceutical (TAK)$41.4B
Merck (MKKGY)$18.5B
Sandoz Group AG (SDZNY)$18.2B
Astellas Pharma (ALPMY)$17.5B
United Therapeutics (UTHR)$16.1B
Neurocrine Biosciences (NBIX)$13.7B
Summit Therapeutics (SMMT)$13.6B
Shionogi (SGIOY)$11.7B
Madrigal Pharmaceuticals (MDGL)$6.4B
Orion OYJ (ORINY)$6.2B
Ionis Pharmaceuticals (IONS)$5.6B
Corcept Therapeutics (CORT)$5.4B
Crinetics Pharmaceuticals (CRNX)$4.9B
PTC Therapeutics (PTCT)$3.5B
Catalyst Pharmaceuticals (CPRX)$2.6B
Dyne Therapeutics (DYN)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.4B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$2.3B
Soleno Therapeutics (SLNO)$1.9B
Recursion Pharmaceuticals (RXRX)$1.7B
Xencor (XNCR)$1.7B
Indivior (INDV)$1.6B
Evotec AG (EVO)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Guardian Pharmacy Services (GRDN)$1.4B
Ocular Therapeutix (OCUL)$1.3B
Aurinia Pharmaceuticals Inc (AUPH)$1.3B
Harrow (HROW)$1.2B